-
Published on Sep 27, 2016
Speaking
to Proactive's stocktube team, chief executive of Silence Therapeutics PLC (LON:SLN) Ali Mortazavi highlighted the progress the biotech firm
has made and reiterated that, at its core, it was a drug development
firm.
"We are trying to make novel drugs," he said, adding that the focus of its development products were on the human liver.
All biotech companies are made up of important intellectual property (IP) and its products, he added.
Relating to its IP, the firm is involved in some complex legal maneuverings, and it looks out for any company which starts to develop a drug in the RNA space, in which as yet no drug has approval. That's because it could potentially infringe on Silence’s IP.
An early example of a licensing deal came from Quark Pharmaceuticals, which licensed Silence’s technology ten years ago and is a partner with the group and has development drugs now in phase II and phase III clinical trials.
The two are currently however in arbitration over a $3mln milestone payment, which Silence believes it is owed.
Mortazavi pointed out however that this dispute has nothing to do with payments that will be due when and if the drugs are approved.
Earlier, in its interim results update, the firm revealed it will seek a partner for its flagship pancreatic cancer drug Atu027 following the release earlier this year of results from its phase II clinical trial.
http://www.4-traders.com/SILENCE-THERAPEUTICS-PLC-13519369/
www.silence-therapeutics.com/
Silence Therapeutics PLC (LON:#SLN) Ali Mortazavi - https://t.co/7KBbt0tNrJ -— DirectorsTalk (@DirectorsTalk) September 27, 2016
Next steps for pancreatic cancer program, dose optimising & full Phase 2 trial.Important opportunity as current 5 year survival rate just 3%— Silence Therapeutics (@SilenceTheraPlc) June 1, 2015
No comments:
Post a Comment